Ketamine vs Psilocybin Therapy: What Patients Need to Know

Ketamine vs psilocybin therapy comes down to one practical reality: ketamine is an FDA-approved medication that licensed providers can prescribe off-label right now, while psilocybin remains a Schedule I controlled substance with only limited legal access. Both have shown fast, meaningful relief for depression, anxiety, and PTSD in clinical research, and both appear to work partly by promoting neuroplasticity, the brain's ability to form new neural connections and reorganize existing ones. Where they differ sharply is legal status, treatment experience, cost, and how long relief tends to last.

This guide compares ketamine and psilocybin therapy across the factors that matter most when deciding which path fits your situation, your timeline, and what is actually accessible to you right now.

Legal Status: The Most Important Practical Difference

Ketamine is a legal, FDA-approved medication that has been used as an anesthetic since 1970. Licensed medical providers can prescribe it off-label, at lower doses, for depression, anxiety, PTSD, and other conditions. Spravato (esketamine nasal spray) carries a specific FDA approval for treatment-resistant depression, separate from generic ketamine. See how Spravato compares to generic ketamine for a closer look at that distinction. Thousands of clinics and telehealth providers across the United States offer ketamine therapy today.

Psilocybin is a Schedule I controlled substance under federal law. A Schedule I classification is the DEA's most restrictive drug category, reserved for substances the federal government considers to have no accepted medical use and a high potential for abuse, according to the DEA's drug scheduling guide. That status is starting to shift. Oregon has implemented a supervised psilocybin services program, detailed on the Oregon Health Authority website, Colorado has passed legislation creating a regulated access framework, and several cities have decriminalized possession. The FDA has also granted psilocybin a Breakthrough Therapy designation for treatment-resistant depression, a program the FDA uses to speed development and review of drugs that show substantial improvement over existing therapies for serious conditions. For a broader look at how policy is moving, see our psychedelic policy roundup.

The practical takeaway: ketamine therapy is accessible right now through established medical channels, while psilocybin therapy is available only in limited legal settings, and broader access is likely still years away.

How Each Substance Works in the Brain

Ketamine

Ketamine is an NMDA receptor antagonist, meaning it blocks a receptor in the brain's glutamate system, the main excitatory neurotransmitter pathway. Blocking NMDA receptors triggers a cascade of downstream effects that promote new synaptic connections, a process researchers believe drives ketamine's fast-acting antidepressant effects. According to the National Institute of Mental Health, rapid-acting treatments like ketamine represent a departure from traditional antidepressants that can take weeks to produce a response. Ketamine also interacts with opioid, GABA, and other neurotransmitter systems, though the relative importance of those interactions is still being studied. For more on what happens if response changes over time, see our guide to NMDA antagonist discontinuation rates.

Psilocybin

Psilocybin converts in the body to psilocin, which primarily activates serotonin 2A receptors, a receptor type involved in mood, perception, and cognition. That activation produces the psychedelic experience and appears to increase communication between brain networks that do not normally interact, a pattern researchers describe as increased neural entropy. Like ketamine, psilocybin appears to promote neuroplasticity, but through a different biochemical pathway.

The Treatment Experience

Ketamine Sessions

A ketamine session typically lasts one to two and a half hours, depending on the administration method. For a full breakdown of what a single visit involves, see how long a ketamine session lasts. During an IV infusion, effects begin within minutes and peak around 20 to 30 minutes in. Patients commonly describe feelings of floating or dissociation, an altered sense of time and space, and sometimes visual imagery, while generally remaining aware they are in a treatment setting. Effects wear off within one to two hours after the session ends. Most treatment protocols start with an initial series of six sessions over two to three weeks, followed by maintenance sessions as needed.

Psilocybin Sessions

A psilocybin session is a longer undertaking. The drug experience itself lasts four to six hours, and preparation and integration sessions add substantially to the overall time commitment. In clinical and supervised settings, psilocybin is typically given in one to three sessions, often spaced weeks apart, with two trained facilitators present throughout. The experience is generally more immersive and psychologically intense than ketamine's, with patients reporting vivid imagery, strong emotional content, and sometimes difficult passages that facilitators help them work through. Preparation sessions beforehand are meant to help patients understand what to expect. Trial results for psilocybin-based compounds, such as the COMP360 phase 3 six month data, give a sense of how durable these effects can be in a research setting.

Cost and Accessibility Considerations

Exact pricing varies by clinic, dosing method, and location, so treat any specific figure you see elsewhere with caution unless it comes directly from a provider. What drives the cost difference between the two therapies is largely staffing and session length. A psilocybin session requires two trained facilitators present for four to six hours, plus separate preparation and integration appointments, which adds up to a much larger time investment than a typical ketamine visit. Ketamine sessions are shorter and more standardized, which is part of why clinics and telehealth providers have been able to scale access more quickly. Where you live also affects access more for psilocybin than for ketamine: outside Oregon's supervised program or an active clinical trial, legal psilocybin therapy is not currently available in the United States, while ketamine clinics operate in most metro areas and by telehealth in many states.

Before committing to either path, walk through these questions with a licensed provider. For a deeper list specific to ketamine care, see our guide on questions to ask a ketamine provider.